Revolution Medicines (RVMD) Other Accumulated Expenses (2019 - 2026)

Revolution Medicines has reported Other Accumulated Expenses for 8 years, with the latest figure at $5.1 million in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 1013.64% year-over-year to $5.1 million in Q2 2026; TTM through Jun 2026 was $5.1 million, a 1013.64% increase from a year earlier, with the FY2025 full-year figure at $7.9 million, up 1247.86% from the prior year.
• Other Accumulated Expenses was $5.1 million for Q2 2026 at Revolution Medicines, up from $3.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.2 million in Q3 2025, with the low at $280000.0 in Q1 2022.
• Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $649000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 85.04% in 2024, then soared 1247.86% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $505000.0 in 2022, then soared by 671.49% to $3.9 million in 2023, then tumbled by 85.04% to $583000.0 in 2024, then jumped by 1247.86% to $7.9 million in 2025, then tumbled by 34.53% to $5.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $5.1 million (Q2 2026), $3.3 million (Q1 2026), and $7.9 million (Q4 2025), per Business Quant data.